Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All metformin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchMetforminMetformin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection

Hariyanto et al., Obesity Medicine, doi:10.1016/j.obmed.2020.100290
Aug 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Metformin for COVID-19
3rd treatment shown to reduce risk in July 2020
 
*, now with p < 0.00000000001 from 93 studies.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,500+ studies for 81 treatments. c19early.org
Meta analysis of 5 studies showing lower mortality with metformin use.
22 meta analyses show significant improvements with metformin for mortality1-21, hospitalization7,13, progression1, and severity8,9,13.
Currently there are 93 metformin for COVID-19 studies, showing 35% lower mortality [31‑39%], 33% lower ventilation [17‑46%], 17% lower ICU admission [6‑26%], 18% lower hospitalization [11‑23%], and 5% fewer cases [-4‑13%].
Hariyanto et al., 18 Aug 2020, peer-reviewed, 2 authors.
This PaperMetforminAll
Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection
Timotius Ivan Hariyanto, Andree Kurniawan
Obesity Medicine, doi:10.1016/j.obmed.2020.100290
Background and aims: The coronavirus disease 2019 (COVID-19) pandemic has caused a significant impact on all aspects of life. One of the comorbidities associated with severe outcome and mortality of COVID-19 is diabetes. Metformin is one of the drugs which is most commonly used for the treatment of diabetes patients. This study aims to analyze the potential benefit of metformin use in reducing the mortality rate from COVID-19 infection. Methods: We systematically searched the Google Scholar database using specific keywords related to our aims until August 3rd, 2020. All articles published on COVID-19 and metformin were retrieved. Statistical analysis was done using Review Manager 5.4 software. Results: A total of 5 studies with a total of 6937 patients were included in our analysis. Our meta-analysis showed that metformin use is associated with reduction in mortality rate from COVID-19 infections [RR 0.54 (95% CI 0.32-0.90), p = 0.02, I 2 = 54%, random-effect modelling]. Conclusion: Metformin has shown benefits in reducing the mortality rate from COVID-19 infections. Patients with diabetes should be advised to continue taking metformin drugs despite COVID-19 infection status.
References
Al-Benna, Association of high level gene expression of ACE2 in adipose tissue with mortality of COVID-19 infection in obese patients, Obes Med, doi:10.1016/j.obmed.2020.100283
Bramante, Ingraham, Murray, Marmor, Hoversten et al., Observational Study of Metformin and Risk of Mortality in Patients Hospitalized with Covid-19, doi:10.1101/2020.06.19.20135095
Chen, Yang, Cheng, Chen, Peng et al., Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication, Diabetes Care, doi:10.2337/dc20-0660
Crouse, Grimes, Li, Might, Ovalle et al., Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes, doi:10.1101/2020.07.29.20164020
Hariyanto, Kurniawan, Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection, Diabetes Metab Syndr, doi:10.1016/j.dsx.2020.07.054
Hariyanto, Kurniawan, Thyroid disease is associated with severe coronavirus disease 2019 (COVID-19) infection, Diabetes Metab Syndr, doi:10.1016/j.dsx.2020.07.044
Huang, Lim, Pranata, Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -a systematic review, meta-analysis, and meta-regression, Diabetes Metab Syndr, doi:10.1016/j.dsx.2020.04.018
Luo, Qiu, Liu, Liu, Zheng et al., Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis, Am. J. Trop. Med. Hyg, doi:10.4269/ajtmh.20-0375
Sharma, Ray, Sadasivam, Metformin in COVID-19: a possible role beyond diabetes, Diabetes Res. Clin. Pract, doi:10.1016/j.diabres.2020.108183
Singh, Gupta, Ghosh, Misra, Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations, Diabetes Metab Syndr, doi:10.1016/j.dsx.2020.04.004
Ursini, Ciaffi, Landini, Meliconi, COVID-19 and diabetes: is metformin a friend or foe?, Diabetes Res. Clin. Pract, doi:10.1016/j.diabres.2020.108167
Wang, Van Oekelen, Mouhieddine, Del, Valle et al., A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward, J. Hematol. Oncol, doi:10.1186/s13045-020-00934-x
{ 'indexed': {'date-parts': [[2022, 3, 28]], 'date-time': '2022-03-28T12:48:26Z', 'timestamp': 1648471706104}, 'reference-count': 12, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2020, 9, 1]], 'date-time': '2020-09-01T00:00:00Z', 'timestamp': 1598918400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'content-domain': { 'domain': [ 'clinicalkey.jp', 'clinicalkey.com', 'clinicalkey.es', 'clinicalkey.com.au', 'clinicalkey.fr', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'short-container-title': ['Obesity Medicine'], 'published-print': {'date-parts': [[2020, 9]]}, 'DOI': '10.1016/j.obmed.2020.100290', 'type': 'journal-article', 'created': {'date-parts': [[2020, 8, 18]], 'date-time': '2020-08-18T17:44:19Z', 'timestamp': 1597772659000}, 'page': '100290', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 61, 'title': [ 'Metformin use is associated with reduced mortality rate from coronavirus disease 2019 ' '(COVID-19) infection'], 'prefix': '10.1016', 'volume': '19', 'author': [ {'given': 'Timotius Ivan', 'family': 'Hariyanto', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-5219-9029', 'authenticated-orcid': False, 'given': 'Andree', 'family': 'Kurniawan', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.obmed.2020.100290_bib1', 'doi-asserted-by': 'crossref', 'first-page': '100283', 'DOI': '10.1016/j.obmed.2020.100283', 'article-title': 'Association of high level gene expression of ACE2 in adipose tissue ' 'with mortality of COVID-19 infection in obese patients', 'volume': '19', 'author': 'Al-Benna', 'year': '2020', 'journal-title': 'Obes Med'}, { 'key': '10.1016/j.obmed.2020.100290_bib2', 'series-title': 'Observational Study of Metformin and Risk of Mortality in Patients ' 'Hospitalized with Covid-19', 'author': 'Bramante', 'year': '2020'}, { 'issue': '7', 'key': '10.1016/j.obmed.2020.100290_bib3', 'doi-asserted-by': 'crossref', 'first-page': '1399', 'DOI': '10.2337/dc20-0660', 'article-title': 'Clinical characteristics and outcomes of patients with diabetes and ' 'COVID-19 in association with glucose-lowering medication', 'volume': '43', 'author': 'Chen', 'year': '2020', 'journal-title': 'Diabetes Care'}, { 'key': '10.1016/j.obmed.2020.100290_bib4', 'article-title': 'Metformin use is associated with reduced mortality in a diverse ' 'population with COVID-19 and diabetes', 'author': 'Crouse', 'year': '2020', 'journal-title': 'medRxiv'}, { 'issue': '5', 'key': '10.1016/j.obmed.2020.100290_bib5', 'doi-asserted-by': 'crossref', 'first-page': '1429', 'DOI': '10.1016/j.dsx.2020.07.044', 'article-title': 'Thyroid disease is associated with severe coronavirus disease 2019 ' '(COVID-19) infection', 'volume': '14', 'author': 'Hariyanto', 'year': '2020', 'journal-title': 'Diabetes Metab Syndr'}, { 'issue': '5', 'key': '10.1016/j.obmed.2020.100290_bib6', 'doi-asserted-by': 'crossref', 'first-page': '1463', 'DOI': '10.1016/j.dsx.2020.07.054', 'article-title': 'Dyslipidemia is associated with severe coronavirus disease 2019 ' '(COVID-19) infection', 'volume': '14', 'author': 'Hariyanto', 'year': '2020', 'journal-title': 'Diabetes Metab Syndr'}, { 'issue': '4', 'key': '10.1016/j.obmed.2020.100290_bib7', 'doi-asserted-by': 'crossref', 'first-page': '395', 'DOI': '10.1016/j.dsx.2020.04.018', 'article-title': 'Diabetes mellitus is associated with increased mortality and severity ' 'of disease in COVID-19 pneumonia - a systematic review, meta-analysis, ' 'and meta-regression', 'volume': '14', 'author': 'Huang', 'year': '2020', 'journal-title': 'Diabetes Metab Syndr'}, { 'issue': '1', 'key': '10.1016/j.obmed.2020.100290_bib8', 'doi-asserted-by': 'crossref', 'first-page': '69', 'DOI': '10.4269/ajtmh.20-0375', 'article-title': 'Metformin treatment was associated with decreased mortality in COVID-19 ' 'patients with diabetes in a retrospective analysis', 'volume': '103', 'author': 'Luo', 'year': '2020', 'journal-title': 'Am. J. Trop. Med. Hyg.'}, { 'key': '10.1016/j.obmed.2020.100290_bib9', 'doi-asserted-by': 'crossref', 'first-page': '108183', 'DOI': '10.1016/j.diabres.2020.108183', 'article-title': 'Metformin in COVID-19: a possible role beyond diabetes', 'volume': '164', 'author': 'Sharma', 'year': '2020', 'journal-title': 'Diabetes Res. Clin. Pract.'}, { 'issue': '4', 'key': '10.1016/j.obmed.2020.100290_bib10', 'doi-asserted-by': 'crossref', 'first-page': '303', 'DOI': '10.1016/j.dsx.2020.04.004', 'article-title': 'Diabetes in COVID-19: prevalence, pathophysiology, prognosis and ' 'practical considerations', 'volume': '14', 'author': 'Singh', 'year': '2020', 'journal-title': 'Diabetes Metab Syndr'}, { 'key': '10.1016/j.obmed.2020.100290_bib11', 'doi-asserted-by': 'crossref', 'first-page': '108167', 'DOI': '10.1016/j.diabres.2020.108167', 'article-title': 'COVID-19 and diabetes: is metformin a friend or foe?', 'volume': '164', 'author': 'Ursini', 'year': '2020', 'journal-title': 'Diabetes Res. Clin. Pract.'}, { 'issue': '1', 'key': '10.1016/j.obmed.2020.100290_bib12', 'doi-asserted-by': 'crossref', 'first-page': '94', 'DOI': '10.1186/s13045-020-00934-x', 'article-title': 'A tertiary center experience of multiple myeloma patients with ' 'COVID-19: lessons learned and the path forward', 'volume': '13', 'author': 'Wang', 'year': '2020', 'journal-title': 'J. Hematol. Oncol.'}], 'container-title': ['Obesity Medicine'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S245184762030110X?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S245184762030110X?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2020, 11, 25]], 'date-time': '2020-11-25T06:11:48Z', 'timestamp': 1606284708000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 9]]}, 'references-count': 12, 'alternative-id': ['S245184762030110X'], 'URL': 'http://dx.doi.org/10.1016/j.obmed.2020.100290', 'relation': {}, 'ISSN': ['2451-8476'], 'issn-type': [{'value': '2451-8476', 'type': 'print'}], 'subject': [ 'Public Health, Environmental and Occupational Health', 'Endocrinology, Diabetes and Metabolism', 'Internal Medicine'], 'published': {'date-parts': [[2020, 9]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Metformin use is associated with reduced mortality rate from coronavirus ' 'disease 2019 (COVID-19) infection', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'Obesity Medicine', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.obmed.2020.100290', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2020 Elsevier Ltd. All rights reserved.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '100290'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit